NuVasive upgraded to Equal Weight from Underweight at First Analysis theflyonthewall.com Fri, Nov 16, 2012, 5:12 AM First Analysis upgraded NuVasive based on valuation and its attractive product portfolio. Price target is $17. View Comments Terms and Privacy Policy Your Privacy Choices Utah Privacy Notice More Info Recommended Stories